iGEM team going green with printer ink – Lethbridge Herald
|
iGEM team going green with printer ink
Lethbridge Herald The group will be working to try to solve both issues using synthetic biology to create pigment substitutes – like the black, cyan, magenta and yellow found in printer ink – that can be found in nature. Synthetic biology is the design and construction … |
Express.co.uk |
Vitamin C may encourage blood cancer stem cells to die
Medical Xpress Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published … Blood cancer: High doses of vitamin C could encourage stem cells to dieExpress.co.uk Vitamin C helps genes to kill off cells that would cause cancerNew Scientist |
Express.co.uk |
Vitamin C may encourage blood cancer stem cells to die
Medical Xpress Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published … Blood cancer: High doses of vitamin C could encourage stem cells to dieExpress.co.uk Vitamin C helps genes to kill off cells that would cause cancerNew Scientist Vitamin C may stop leukemia from progressingMedical News Today The Scientist all 6 news articles » |
|
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Nasdaq As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc. ‘s PFE newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant. Pfizer’s shares are up 5.8% so far … |
Medical Xpress |
Scientists develop novel immunotherapy technology for prostate cancer
Medical Xpress “This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,” said David B. Weiner, Ph.D., executive vice president of The Wistar … |
|
BioMarin to Include Additional Phase 3 Trial for Hemophilia A Gene Therapy
Specialty Pharmacy Times An additional phase 3 study investigating the novel gene therapy BMN 270 for the treatment of hemophilia A will be added as part of BioMarin Pharmaceutical’s development plan for the drug. Two separate studies will be conducted to examine the safety … |